Q-omics provides the consensus-scored LINC00102 profile across patient tissues and cancer cell-line models. LINC00102 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, LINC00102 is differentially expressed in 5, with the highest sampling consensus in KIRC. Additionally, LINC00102 RNA expression shows 9,917 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UVM, KIRC, and THYM as cancer lineages where LINC00102 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC00102 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC00102 survival associations across molecular data types. LINC00102 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC00102 RNA expression–survival associations across cancer types. High LINC00102 expression shows unfavorable associations in UVM, UCS and KICH, but favorable associations in SKCM, BRCA and BLCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .004). Together, the overview and detailed table identify UVM as the clearest survival context for LINC00102 RNA expression.
This table summarizes LINC00102 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC00102. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC00102 shows lower tumor expression in KICH and higher tumor expression in KIRC, LIHC, READ and CHOL. The KIRC box plot shows higher LINC00102 RNA expression in tumor versus normal tissue (log2 FC = +0.030, t-test p = .007).
This table shows molecular features associated with LINC00102 in patient tissues and cancer cell lines. In patient samples, LINC00102 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
